The THINK trial (NCT03018405) evaluated anti-NKG2D CAR-T (CYAD-01) for myeloid malignancies without preconditioning or bridging therapy, aiming to reduce stress-induced NKG2D ligand expression on healthy cells. The gene discussed is KLRK1; the disease is myeloid neoplasm.